Whoop
FDA drops enforcement against Whoop after it tweaks blood pressure feature
· By Endurance Wire
The Food and Drug Administration quietly told wearable maker Whoop last week that it would not take further enforcement action over a controversial feature that gives users a reading of their blood pressure. In July 2025, the agency warned Whoop for releasing its Blood Pressure Insights feature without clearance, saying it was a medical device that required review. “The product is intended to provide a measurement or estimation of a user’s blood pressure, which is inherently associated with the diagnosis of hypo- and hypertension,” the agency wrote in its warning letter .
More Whoop this month
- Oura, Whoop Push Deeper Into Healthcare
- FDA closes warning letter to Whoop for blood pressure insights feature
- FDA closes warning letter to Whoop for blood pressure insights feature
- FDA drops blood pressure device enforcement against Whoop
- Whoop fitness tracker has a rare deal for Prime Day
- FDA drops Whoop warning letter over blood pressure feature